Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The revision label on the page updated from v3.3.3 to v3.3.4, reflecting a small metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:18:42.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Added a consolidated Locations section listing study sites by state (California, Colorado, Florida, Indiana, Iowa, Massachusetts, Michigan, Minnesota, Tennessee, Texas, Utah, Virginia). Removed the individual per-state location sections and updated the page to Revision: v3.3.3.
    Difference
    1%
    Check dated 2025-12-23T09:22:58.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and v3.3.1 was removed; no changes to the study details page are visible.
    Difference
    0.0%
    Check dated 2025-12-01T17:28:33.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The Publications section now states that publications are automatically filled from PubMed, and the Revision tag shows v3.3.1 (previously v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T13:43:44.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The government funding status notice warning about potential data that may be out of date has been removed from the page.
    Difference
    0.3%
    Check dated 2025-11-17T06:37:33.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    Added a comprehensive Results section with primary and secondary outcomes and safety data for NCT02880371. The section includes ORR, DOR, PFS, OS, irRR, and adverse events.
    Difference
    0.3%
    Check dated 2025-11-03T01:11:38.000Z thumbnail image

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.